Table 1.

Baseline clinical features of 10 patients with transformed SCLC from EGFR-mutant LUAD.

Case No.	Age (Years)	Smoking status	Gender	Stage	Initial mutation status (specimen type)	Primary tumor lesion	TKI therapy before transformation	Time to SCLC transformation (months)	Comorbidities	Specimen type (2nd NGS)
1	62	Yes	Male	IIIB	EGFR exon 19 del (tissue)	left lower lung	Osimertinib	19	chronic bronchitis	tissue
2	54	Never	Female	IVA	EGFR exon 19 del (tissue)	right lower lung	Osimertinib	22	none	tissue
3	46	Never	Male	IVB	EGFR exon 21 L858R, (tissue)	right middle lung	Osimertinib	17	none	pleural fluid
4	59	Yes	Male	IIIB	EGFR exon 19 del, (tissue)	left upper lung	Aumolertinib	23.5	chronic bronchitis	lymph node
5	67	Yes	Female	IIIB	EGFR exon 19 del, T790M (+) (tissue)	right lower lung	Aumolertinib	21	obstructive emphysema	tissue
6	38	Yes	Male	IVB	EGFR exon 21 L858R, (tissue)	right lower lung	Osimertinib	16	chronic bronchitis	pleural fluid
7	46	Yes	Male	IIIB	EGFR exon 19 del, (tissue)	left lower lung	Osimertinib	22.5	chronic bronchial asthma	tissue
8	61	Yes	Female	IVA	EGFR exon 21 L858R, (tissue)	right upper lung	Osimertinib	19.5	chronic bronchial asthma	lymph node
9	57	Never	Male	IVA	EGFR exon 19, (tissue)	right lower lung	Aumolertinib	20.5	diabetes mellitus	lymph node
10	59	Never	Male	IVB	EGFR exon 21 L858R, T790M (+) (tissue)	left lower lung	Osimertinib	25.5	hypertension	tissue